17 Mar 2025 • A meta-analysis of four phase-III RCTs (1,837 lung cancer patients) confirms Tislelizumab's survival benefits.

The anti-PD-1 therapy significantly improved overall survival (HR: 0.72) and progression-free survival (HR: 0.61) in NSCLC and SCLC, with similar efficacy as monotherapy or with chemotherapy.

With low study heterogeneity and follow-ups of 14.2–16.7 months, findings reinforce its role in lung cancer treatment, though more SCLC trials are needed to refine patient-specific strategies.

Source: Cureus | Read Full Story